To bring the patient perspective to the forefront of the drug development process, the GBS|CIDP Foundation hosted an externally led Patient-Focused Drug Development (EL PFDD) meeting on May 16th to elevate the patient voice of those with MMN, GBS, and Anti-Mag. The audience consisted of regulators and researchers involved in the drug development process, this meeting highlighted the needs and preferences of the MMN, GBS, and Anti-Mag patient communities. For more information visit: https://www.gbs-cidp.org/2024elpfdd/
00:00 Introduction
12:51 MMN Disease Overview by Dr. Jeff Allen
27:51 MMN Panelist Stories
44:20 MMN Symptoms, Impact and Management
1:23:28 MMN Treatments
1:58:43 Anti-MAG Disease Overview by Dr. Michelle Mauermann
2:11:27 Anti-MAG Panelist Stories
2:28:07 Anti-MAG Symptoms, Impact and Management
3:05:37 Anti-MAG Treatments
3:39:41 GBS Disease Overview by Dr. Bart Jacobs
3:51:47 GBS Panelist Stories
4:07:52 GBS Symptoms, Impact and Management
4:32:55 Treatment of GBS and Long-Lasting Impacts